Gender Differences in VLDL1 and VLDL2 Triglyceride Kinetics and Fatty Acid Kinetics in Obese Postmenopausal Women and Obese Men

University of Cambridge, Cambridge, England, United Kingdom
The Journal of Clinical Endocrinology and Metabolism (Impact Factor: 6.21). 04/2012; 97(7):2475-81. DOI: 10.1210/jc.2011-3248
Source: PubMed


High plasma triglycerides (TG) have been shown to be independent and better predictors of cardiovascular disease than low-density lipoprotein (LDL) cholesterol in women. This may be due to gender differences in very-low-density lipoprotein 1 (VLDL(1))- and VLDL(2)-TG and fatty acid kinetics.
Our objective was to investigate whether there are differences in VLDL(1)- and VLDL(2)-TG and fatty acid kinetics in obese men and postmenopausal women, a high risk group for cardiovascular disease.
Stable isotopes techniques were used to measure fasting palmitate rate of appearance, metabolic clearance rate, oxidation rate, and nonoxidative disposal rate, VLDL(1)-TG and VLDL(2)-TG fractional catabolic rate (FCR) and production rate (PR). Whole-body fat distribution was measured by magnetic resonance imaging.
Participants included 10 postmenopausal obese women and eight obese men matched for age, body mass index, and fasting plasma TG.
The women had lower visceral fat and higher sc fat than the men (P < 0.001 and P < 0.002). Palmitate rate of appearance, metabolic clearance rate, nonoxidative disposal rate, and oxidation rate corrected for resting energy expenditure were greater in the women than the men (all P < 0.03). VLDL(2)-TG PR corrected for fat-free mass was higher in the women (P < 0.001). VLDL(2)-TG and VLDL(2)-cholesterol pools were higher in the women (P < 0.001 and P < 0.008). VLDL(1)-TG FCR and PR and VLDL(2)-TG FCR were not different between genders.
Fatty acid and VLDL(2)-TG flux is higher in postmenopausal obese women than in obese men matched for fasting plasma TG levels.

Download full-text


Available from: Jimmy David Bell, Mar 06, 2015
  • Source
    • "Previous works have reported decrease in plasma TC concentrations of overall leukemia patients while we did not see this effect in the overall analysis. Major differences in the lipoprotein metabolism of healthy men and women have been reported [42]. It is possible that the effects of tumor burden on lipoprotein metabolism are also different in the two genders. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Previous studies appreciate the leukemia-associated alterations in plasma lipid profiles but fail to provide a consistent pattern of lipid anomalies in leukemia patients. These inconsistencies could be due to overlooking the effects of related confounding risk-factors and comorbidities. The plasma lipid profiles of acute-leukemia and control groups were compared. We observed that acute lymphocytic leukemia (ALL) patients display significantly higher triglycerides and very low-density lipoproteins, whereas, acute myeloid leukemia (AML) patients display significantly lower high-density lipoproteins. To assess the confounding effects of related risk factors gender-, age- and BMI-based analyses were performed. We observed that the aforementioned significant differences in the lipid profiles of leukemia patients were restricted to female participants of the respective groups. Moreover, significant decrease in total cholesterol and low-density lipoproteins levels was observed only in male participants of the AML population. Various age-specific trends in plasma lipid profile of the leukemia patients were also observed. BMI-based analysis did not display many significant differences from the overall analyses. In addition to comparing the absolute values of plasma lipids in leukemia and control groups we also compared and observed significant differences in prevalence of various isolated- and mixed-dyslipidemias in these groups. These findings may help in outlining the prevalence and types of dyslipidemia in leukemia patients that may emerge as diagnostic/prognostic factors for management of acute leukemia. Copyright © 2015. Published by Elsevier B.V.
    Full-text · Article · Feb 2015 · Clinica Chimica Acta
  • [Show abstract] [Hide abstract]
    ABSTRACT: Plasma free fatty acids (FFA) are major substrates for hepatic VLDL-triglycerides (VLDL-TG) production. In addition, it is a common belief that VLDL-TG production is a substrate driven process primarily determined by systemic FFA delivery. This review summarizes recent research of our understanding of the regulation of VLDL-TG production. Recent studies have shown that increasing FFA flux is not inevitably associated with increased VLDL-TG production. Exercise induced increase in FFA flux resulting in unchanged VLDL-TG production in lean patients as well as in obese patients with increased hepatic fat despite exercise reduced hepatic fat content. With respect to the other inseparable conditions of insulin resistance and hyperinsulinemia, recent studies demonstrate that increased hepatic VLDL-TG production precedes the insulin resistance-associated impairment of the regulation of hepatic glucose production, whereas isolated chronic hyperinsulinemia (insulinoma) was not associated with increased VLDL-TG production. Insulin has been shown to have acute potent temporary suppressing effect on VLDL-TG production and new data demonstrates that increased glucagon reduces VLDL-TG production. Finally, recent studies indicate that sex hormones, oestrogen and testosterone, have no or very modest impact on VLDL-TG production. Regulation of hepatic VLDL-TG production involves interplay between systemic FFA delivery, hormonal, and nutritional factors that act in concert with hepatic fatty acid handling to regulate short-term and long-term VLDL-TG production. The results of recent studies underscore that our current understanding of these relationships is complex and needs further research.
    No preview · Article · May 2012 · Current opinion in lipidology
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: The study aimed to 1] develop a method which completely separated hepatic (VLDL1, VLDL2) and intestinal (chylomicron, CM) lipoproteins and 2] use the method to measure triacylglycerol (TAG) kinetics in these lipoproteins in the fed and fasting state in healthy subjects using intravenous (2)H5-glycerol as the tracer. An immunoaffinity method which completely separated hepatic and intestinal particles using sequential binding to three antibodies to apolipoprotein B100 (apoB100) was established and validated. Six healthy volunteers were studied in a fasted and continuous feeding study (study 1). Five additional healthy volunteers were studied in a continuous feeding study which included an oral (13)C3-glycerol tripalmitin tracer (study 2). In both studies an intravenous bolus of (2)H5-glycerol was administered to label TAG in hepatic and intestinal lipoproteins. In both feeding studies there was sufficient incorporation of the glycerol tracer into the exogenous lipoproteins to enable isotopic enrichment to be measured. In study 2 the oral tracer enrichment in VLDL1 was <5% of CM enrichment, 150 minutes after tracer administration demonstrating negligible contamination of VLDL1 with apoB48. Western blotting showed no detectable apoB100 in CMs. VLDL1 and VLDL2 TAG fractional catabolic rate (FCR) did not differ between feeding and fasting (study 1). There was no difference between CM and VLDL1 TAG FCR in both fed studies. In fed study 2, 47% of the total TAG production rate (CM+VLDL1) was from CM. This methodology may be a useful tool for understanding the abnormalities in postprandial TAG kinetics in metabolic syndrome and type 2 diabetes.
    Full-text · Article · Apr 2013 · AJP Endocrinology and Metabolism
Show more